Law360 (April 9, 2019, 1:38 PM EDT) -- The Trump administration, as part of the U.S. Department of Health and Human Services' "Blueprint to Lower Drug Prices and Out-of-Pocket Costs," has put forth several proposals to reduce the prices patients pay for prescription medications. One sensible proposal aims to directly lower prices for consumers by encouraging discounts be passed on to patients at the point of sale. If adopted, this rule promises to streamline cost savings for American patients and shake up certain entrenched interests, whose ire it has already drawn.
Under the status quo, drug manufacturers start from a set of list prices, but provide retrospective rebates to...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!